Read by QxMD icon Read

How I treat early relapsing follicular lymphoma

Carla Casulo, Paul M Barr
Blood 2019 January 30
Follicular lymphoma (FL) is the most frequently occurring indolent non-Hodgkin lymphoma with generally favorable outcomes, but a variable clinical course. Recent studies have elucidated the consistent and reproducible frequency of early disease progression in FL, occurring in approximately 20% of patients. Relapse of FL within 24 months of chemoimmunotherapy (POD24) is now established as a robust marker of poor survival, leading to increased risk of death. Currently there is no established method of identifying patients at risk for early disease progression at the time of their FL diagnosis. However numerous studies worldwide are investigating clinical, pathological, and radiographic biomarkers to help predict POD24, to improve subsequent outcomes and adapt therapy based on individual risk. There is also a paucity of standardized treatments for patients with POD24, but investigations are ongoing testing novel targeted therapies and autologous stem cell transplant strategies. This review provides an overview of early relapsing FL and our approach to patient management based on recent available data.


You need to log in or sign up for an account to be able to comment.

No comments yet, be the first to post one!

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"